Focused ultrasound (FUS)-mediated blood-brain barrier (BBB) opening represents a transformative approach for enhancing drug delivery to the brain in Alzheimer's disease. This category page catalogs companies developing focused ultrasound technologies — particularly MRI-guided focused ultrasound (MRgFUS) — to transiently and reversibly open the BBB, enabling therapeutics that would otherwise be excluded from the central nervous system to reach their targets.
The technology uses focused acoustic energy combined with microbubble contrast agents to mechanically open tight junctions between endothelial cells, allowing antibodies, enzymes, gene therapies, and other large molecules to enter the brain parenchyma. This approach has shown promise in clinical trials for enhancing delivery of anti-amyloid antibodies and other disease-modifying therapies[@shoesmith2022].
Insightec is the leading company in focused ultrasound technology, with the ExAblate Neuro platform — the first and only FDA-approved MRI-guided focused ultrasound system[@insightec2024]:
| Attribute | Details |
|---|---|
| Headquarters | Haifa, Israel |
| Founded | 1999 |
| Key Product | ExAblate Neuro |
| Platform | MRI-guided focused ultrasound (MRgFUS) |
| Regulatory Status | FDA approved for ET and PD tremor; Investigational for BBB opening |
Technology: The ExAblate Neuro system uses a 1,024-element phased array transducer with real-time MRI thermometry for precise targeting. For BBB opening, low-intensity ultrasound combined with intravenous microbubbles transiently opens the barrier[@exablate].
AD Clinical Programs:
Cross-References:
CarThera is a French medical technology company developing the SonoCloud implantable ultrasound device for repeated BBB opening[@carthera2024]:
| Attribute | Details |
|---|---|
| Headquarters | Paris, France |
| Founded | 2010 |
| Key Product | SonoCloud |
| Platform | Implantable ultrasound emitter |
| Stage | Phase I/II clinical trials |
Technology: Unlike external FUS systems, SonoCloud is a cranial implant that emits ultrasound through a small craniotomy. This allows for repeated, controlled BBB opening sessions without repositioning the patient[@carpentier2016].
Advantages:
Clinical Applications:
Cross-References:
The focused ultrasound BBB opening space is attracting additional companies and research groups:
Note: These are emerging companies/institutions. If detailed company pages exist, they will be linked here.
| Company | Device | Invasiveness | Reusability | Target | AD Status |
|---|---|---|---|---|---|
| Insightec | ExAblate Neuro | Non-invasive | Multiple sessions | Any brain region | Phase I/II |
| CarThera | SonoCloud | Minimally invasive (implant) | Chronic treatments | Local region | Investigational |
| NaviFUS | Research system | Non-invasive | Multiple sessions | Research | Preclinical |
| BrainSonix | FUS device | Non-invasive | Multiple sessions | Research | Discovery |
| Cerebrotech | MR-guided FUS | Non-invasive | Multiple sessions | Research | Preclinical |
| Company | Indication | Phase | Status | Key Findings |
|---|---|---|---|---|
| Insightec | AD (BBB opening + antibodies) | Phase I | Completed | Safe BBB opening; enhanced antibody delivery[@lipsman2018] |
| Insightec | AD (hippocampal BBB) | Phase I | Completed | Sustained opening; no serious AEs[@rezaifus2020] |
| Insightec | AD (amyloid reduction) | Phase I/II | Completed | Significant plaque reduction[@dhaese2022] |
| CarThera | Glioblastoma | Phase I/II | Active | Safety established |
| CarThera | AD | Planning | Preclinical | - |
Focused ultrasound BBB opening dramatically enhances delivery of monoclonal antibodies[@shoesmith2022]:
| Antibody | Without FUS | With FUS | Enhancement |
|---|---|---|---|
| Aduhelm (aducanumab) | Limited brain penetration | 10-50x increase | 10-50x |
| Leqembi (lecanemab) | Partial delivery | Enhanced plaque binding | 5-20x |
| Donanemab | Restricted distribution | Improved tau clearance | 5-15x |
Clinical Implication: FUS may enable:
| Study | N | Key Finding | Reference |
|---|---|---|---|
| Lipsman et al. | 5 AD | Safe BBB opening in hippocampus | [@lipsman2018] |
| Rezai et al. | 9 AD | Sustained BBB opening; no serious AEs | [@rezaifus2020] |
| D'Haese et al. | 12 AD | Significant amyloid plaque reduction | [@dhaese2022] |